AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01965236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium chloride
Description: Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
Study NCT01351493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric Oxide Gel, once or twice per day, 12weeks
Study NCT01351493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo Gel, once or twice per day, 12weeks
Study NCT03419442 — intervention group
Intervention type: DRUG
Intervention: Xofigo
Description: Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
Study NCT01965236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01391819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
Study NCT01120652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling (SC)
Description: This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
Study NCT02514161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle training
Description: This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
Study NCT02514161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT + Manual Therapy and Motor Control Exercise
Description: The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
Study NCT03419442 — intervention group
Intervention type: DRUG
Intervention: Taxotere
Description: Docetaxel injection 75mg/m2 every 3 weeks
Study NCT01704430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Enteric L-Glutamine
Study NCT01704430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Enteric Maltodextrin
Study NCT03985787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
Study NCT04292366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme
Study NCT04292366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invitation procedure
Description: Optimised invitation procedures in an organised colorectal cancer screening programme
Study NCT02216019 — intervention group
Intervention type: OTHER
Intervention: Whole blood
Description: preoparatoire whole blood and postoperative whole blood
Study NCT03353454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
Study NCT03419442 — intervention group
Intervention type: DRUG
Intervention: Jevtana
Description: Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
Study NCT02658370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: animated home-based exercises (Wii-fit)
Study NCT02658370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: animated home-based exercises (Wii-fit)
Study NCT02658370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional home-based exercise program
Study NCT02658370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional home-based exercise program
Study NCT04232371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: New Ablation Technique
Description: Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
Study NCT04232371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ablation Technique
Description: Ablation performed using the traditional anatomical / electrogram guided ablation approach.
Study NCT00861029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Subjects treated with pazopanib
Study NCT00861029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo for pazopanib
Description: Control for comparison with pazopanib
Study NCT00861029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Comparator for pazopanib
Study NCT00861029 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Comparator for pazopanib
Study NCT00861029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Placebo for moxifloxacin
Study NCT00861029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo for moxifloxacin
Description: Placebo for moxifloxacin
Study NCT00865436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Study NCT00865436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study NCT04217512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole low dose
Description: Pantoprazole 0.6 mg/kg
Study NCT04217512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole high dose
Description: Pantoprazole 1.6 mg\\kg
Study NCT04217512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Description: Standard hydration alone
Study NCT04217512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin
Study NCT03535558 — intervention group
Intervention type: DRUG
Intervention: Fluoroquinolone (FQ)
Description: Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
Study NCT03535558 — intervention group
Intervention type: DRUG
Intervention: Azithromycin (AZ)
Description: Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
Study NCT03535558 — intervention group
Intervention type: DRUG
Intervention: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Description: Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
Study NCT00171184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
Study NCT00171184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily with sham titration
Study NCT01117519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion Therapy
Description: Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
Study NCT03484065 — intervention group
Intervention type: OTHER
Intervention: Questionnaire quality of life
Study NCT03950778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
Study NCT02147678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Study NCT02147678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02147678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
Study NCT02177383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid diet supplementation
Description: Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.
Study NCT02177383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.
Study NCT00934089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329
Description: Topical ocular solution, once-daily for 14 days
Study NCT00934089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost vehicle
Description: Topical ocular solution, once-daily for 14 days
Study NCT01846702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as a SC injection.
Study NCT01846702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3084077
Description: Given as a SC injection.
Study NCT03537638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
Study NCT02914938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: 60 mg
Study NCT02914938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion 375 mg/m2
Study NCT02914938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 80 and 160 mg bid
Study NCT03567707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-section -Vaginal seeding
Description: Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.
Study NCT03567707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-section - Placebo Seeding
Description: Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
Study NCT03567707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
Study NCT01391819 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
Study NCT03946826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halometasone Cream
Description: Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
Study NCT03946826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halometasone Cream
Description: Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
Study NCT03946826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaseline
Description: Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
Study NCT03946826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
Study NCT03946826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
Study NCT00502320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: one 8 mg tablet at bed for up to 4 months
Study NCT00502320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet at bedtime for up to 4 months
Study NCT02680405 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
Study NCT05112614 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study NCT05112614 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT03929913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)
Description: The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
Study NCT05212428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva, blood, urine and stool samples
Study NCT05212428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05212428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive genetic counseling
Study NCT05212428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete family history
Study NCT05212428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01708044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Study NCT02147678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
Study NCT01708044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01468545 — intervention group
Intervention type: OTHER
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
Study NCT01468545 — intervention group
Intervention type: OTHER
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: No extra educational reinforcement.
Study NCT02004301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled T4 Tablet
Study NCT02004301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled T6 Tablet
Study NCT03332147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03264443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
Study NCT03264443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
Study NCT01538914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Postoperative pain is controlled with local analgesics via PVB.
Study NCT02680405 — intervention group
Intervention type: PROCEDURE
Intervention: Skin tape stripping
Description: Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
Study NCT02680405 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
Study NCT01681576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320mg tablet once daily
Study NCT01681576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400mg tablet once daily
Study NCT02271867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: An ultrasound guided ISB was performed with injection aimed to block the C5-root
Study NCT01928485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo active surveillance
Study NCT01928485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunphenon
Description: Given PO
Study NCT01928485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies